Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Prostate cancer patients on hormone therapy at increased risk for various heart diseases

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 22 Sep 2009

Views: 13796

Rating:

Save

Ms Mieke Van Hemelrijck - King's College, London

Ms Mieke Van Hemelrijck of King's College, London, speaking at an official press conference at ECCO 15 ESMO 34, Berlin, 2009: Prostate cancer patients on hormone therapy at increased risk for various heart diseases.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg

ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT...

Prof Andrew Armstrong - Duke University, Durham, USA

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

More from ecancer